Raquel von Schumann

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index765citations35works2.52yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(23), HER2/EGFR in Cancer Research(18), Advanced Breast Cancer Therapies(7), Cancer Treatment and Pharmacology(6), Breast Lesions and Carcinomas(5)

Publications34 total

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials
Annals of Oncology·2025· 2 citedOpen Access
LBA17 Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
Annals of Oncology·2024· 3 cited
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.
Journal of Clinical Oncology·2024· 5 cited
Abstract PS09-01: Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group
Cancer Research·2024
Table of Contents
Annals of Oncology·2023Open Access
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/<i>ERBB2</i>-Positive Early Breast Cancer
JAMA Oncology·2023· 30 citedOpen Access
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
Annals of Oncology·2023· 16 citedOpen Access
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
Journal of Clinical Oncology·2023· 33 cited
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology·2022· 76 cited
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Cancers·2021· 17 citedOpen Access
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
The Breast·2021· 10 citedOpen Access
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Breast Cancer Research·2021· 21 citedOpen Access
Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial
Cancer Research·2021· 11 cited
Early response by <scp>MR</scp> imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the <scp>WSG ADAPT</scp> subtrials
International Journal of Cancer·2021· 11 citedOpen Access
LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results
Annals of Oncology·2020· 6 citedOpen Access
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Research Square (Research Square)·2020· 1 citedOpen Access
De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.
Journal of Clinical Oncology·2020· 14 cited
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients
Breast Care·2020· 3 citedOpen Access
Abstract P2-16-05: Efficacy of response- and toxicity-guided neoadjuvant chemotherapy in elderly early breast cancer patients: Results of WSG ADAPT elderly sub-trial
Cancer Research·2020
Protroca: a non-interventional study on prophylaxis of chemotherapy induced neutropenia using Lipegfilgrastim in non-selected breast cancer patients
Senologie - Zeitschrift für Mammadiagnostik und -therapie·2019
page 1 of 2Next →

Frequent Co-authors

Nadia Harbeck(32), Oleg Gluz(32), Ulrike Nitz(25), Ronald Kates(22), Rachel Wuerstlein(22), Jochem Potenberg(17), Michael Braun(16), Bahriye Aktas(15), Helmut Forstbauer(15), Matthias Christgen(14), Claudia Schumacher(13), Eva‐Maria Grischke(13), Hans Kreipe(13), Monika Graeser(10), Marianne Just(10), Christine zu Eulenburg(9), Sherko Küemmel(8), Christoph Uleer(7), Enrico Pelz(7), Sherko Kümmel(7)